Aurobindo Pharma reported a 10% year-on-year decline in consolidated net profit, which stood at ₹824 crore for the quarter ended June 30, 2025, impacted primarily by weaker performance in its US generics and API (Active Pharmaceutical Ingredients) segments.
The company had posted a net profit of ₹918 crore in the corresponding quarter of the previous fiscal (Q1 FY25). Despite the profit dip, revenue from operations rose to ₹7,868 crore, up from ₹7,567 crore in the same quarter last year, indicating a modest growth of nearly 4%.The decline in profitability comes amid challenges in the US market, which remains a key geography for Aurobindo’s formulations business, along with subdued demand in the API vertical. Aurobindo Pharma shared these financial results in a regulatory filing with the stock exchanges.
